₹51.15 -2.7 -4.9%
Last Trade - 18/09/20
| Market Cap | £219.3m |
| Enterprise Value | £219.1m |
| Revenue | £126.8m |
| Position in Universe | 506th / 3004 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Mar | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 7,967 | 8,933 | 7,672 | 9,127 | 10,001 | 11,342 | +7.3% | ||||
| +43.0 | -21.7 | -89.7 | +363.9 | +94.1 | +53.0 | |||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2020
|
31st Dec 2021
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Marksans Pharma Limited is a pharmaceutical holding company. The Company is engaged in the research, manufacturing and marketing of generic pharmaceutical formulations. The Company's product portfolio addresses various therapeutic segments, including Pain management, Cough and cold, Anti-diabetic, Cardiovascular system, Central nervous system, Antibiotic, Gastrointestinal, Anti-allergic and Miscellaneous. The Company undertakes research and development initiatives, and offers customer relationship management (CRM) services to global pharmaceutical companies. The Company has a manufacturing facility for the manufacture of oral solid tablets and soft gelatin capsules in Goa; a liquids/ointments/sachets manufacturing facility in Southport, the United Kingdom, and a solid oral dosages manufacturing facility in New York, the United States. It supplies products to approximately 20 countries. Its subsidiaries include Nova Pharmaceuticals Australasia Pty Ltd. and Marksans Pharma (UK) Limited.
| Last Annual | March 31st, 2020 |
| Last Interim | June 30th, 2020 |
| Incorporated | April 16, 1992 |
| Public Since | January 4, 2010 |
| No. of Shareholders: | n/a |
| No. of Employees: | 728 |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | |
| Exchange | National Stock Exchange of India |
| Shares in Issue | 409,313,698 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 21 Lotus Business Park, Off New Link Road Andheri (W), MUMBAI, 400053, India |
| Web | http://www.marksanspharma.com/ |
| Phone | +91 22 40012000 |
| Auditors | Bhuta Shah & Co. |
As of 18/09/20, shares in Marksans Pharma are trading at ₹51.15, giving the company a market capitalisation of £219.3m. This share price information is delayed by 15 minutes.
Shares in Marksans Pharma are currently trading at ₹51.15 and the price has moved by 0.261k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Marksans Pharma price has moved by 0.236k% over the past year.
Of the analysts with advisory recommendations for Marksans Pharma, there are there are currently 0 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Marksans Pharma is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Marksans Pharma is scheduled to issue upcoming financial results on the following dates:
The Marksans Pharma dividend yield is 0.2% based on the trailing twelve month period.
Last year, Marksans Pharma paid a total dividend of 0.1, and it currently has a trailing dividend yield of 0.2%. Looking ahead, shares in Marksans Pharma are due to go ex-dividend on 2020-09-22 and the next dividend pay date is 2020-10-08.
Marksans Pharma are due to go ex-dividend on 2020-09-22 and the next dividend pay date is 2020-10-08. The historic dividend yield on Marksans Pharma shares is currently 0.2%.
To buy shares in Marksans Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Marksans Pharma are currently trading at ₹51.15, giving the company a market capitalisation of £219.3m.
Here are the trading details for Marksans Pharma:
Based on an overall assessment of its quality, value and momentum, Marksans Pharma is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Marksans Pharma are currently priced at ₹51.15. At that level they are trading at 39.39% premium to the analyst consensus target price of 0.00.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Marksans Pharma. Over the past six months, the relative strength of its shares against the market has been 0.187k%. At the current price of ₹51.15, shares in Marksans Pharma are trading at 90.47% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Marksans Pharma PE ratio based on its reported earnings over the past 12 months is 14.45. The shares are currently trading at ₹51.15.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Marksans Pharma's management team is headed by:
Here are the top five shareholders of Marksans Pharma based on the size of their shareholding:
